Infinimmune’s platform bypasses traditional discovery methods by reading antibodies directly from human memory B cells. The core insight is that the immune system has already spent a lifetime selecting and validating the most effective antibodies, providing a superior, de-risked starting point for new human therapeutics.

By targeting just one antigen, Zag's therapy recruits other T-cells to the site of inflammation, creating a "bystander suppression" effect. This allows a simple, single-antigen drug to control a complex multi-antigen disease, a more elegant solution than multi-antigen nanoparticle approaches.

An investigational in vivo CAR-T therapy uses viral particles infused directly into the patient to convert their T-cells into CAR-T cells. This approach eliminates the complex steps of apheresis, lymphodepletion, and ex vivo manufacturing, effectively creating an off-the-shelf product that becomes an autologous treatment inside the body.

A therapeutic approach called "T-cell engagers" or "BiTEs" uses engineered antibodies with two different heads. One side binds to a cancer cell, while the other binds to a nearby T-cell. This effectively brings the killer cell and the target together, leveraging the body's existing immune cells without genetic modification.

Create's strategy is not limited to a single cell type. They view success in solid tumors as requiring the programming of all immune cells. Their platform can specifically engineer myeloid cells, T-cells, and NK cells in vivo, orchestrating a coordinated, multi-pronged attack on cancer.

While personalized cancer vaccines require extracting and processing a patient's tumor, Create Medicines' in vivo approach is entirely off-the-shelf. By delivering the programming directly into the body, they enable the patient's own immune system to do the complex, personalized work of attacking the cancer itself.

Early data from an in vivo CAR-T therapy suggests a paradigm shift is possible. By engineering T-cells directly inside the patient with a simple infusion, this approach could eliminate the need for leukapheresis and external manufacturing, completely disrupting the current cell therapy model.

While many cell therapies rely on complex genetic engineering with viral vectors, Adaptin Bio manipulates patient T-cells without it. This simpler, non-viral process is a strategic choice to reduce costs, speed up manufacturing, and make the therapy accessible to a broader patient population.

The T-cell delivery system is versatile. It can carry T-cell engagers for cancer, but also antibodies for Alzheimer's or oligonucleotides. By using different T-cell types (like regulatory T-cells), it can also be used to reduce inflammation, expanding its applicability beyond oncology.